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Abstract   
The skin bleaching industry is a global business with a vast array of anti-melanogenic choices 
including glutathione. Glutathione is synthesized in vivo but has been used as a bodily 
supplement by medical personnel to aid in preventative medicine. Known for its antioxidant 
properties, glutathione has been used for its anti-melanogenic effects. Intravenous glutathione 
requires more investigation to determine its safety for usage. It continues to be distributed to the 
cosmetic industry despite antagonism from the Philippine FDA. This study will research the 
potential effects of intravenous glutathione on women and it will propose the biochemical 
mechanisms of glutathione in induced disease states in women. The aim is to educate people 
about safer methods for skin lightening.  
Keywords: skin lightening, intravenous glutathione, pheomelanin, Fitzpatrick skin types, 
Stevens-Johnson syndrome.    
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Skin Lightening Treatments: A Review on the Effect of Intravenous Glutathione 
in the Disease States of Women 
Skin lightening, more commonly known as skin bleaching, is globally practiced by 
women who are of darker shades of skin. It is a form of body modification performed to alter 
appearance and temporarily alleviate psychological issues that stem from self-hatred and low 
self-esteem.1 Racism and colonialism have attributed greatly to the psychological pressures of 
having lighter skin. Fairer skin is viewed as more attractive, tasteful and healthy.2 Statistically 
speaking, women of African descent participate the most in skin lightening, with 70% of women 
in Nigeria, 30-40% of women in Pretoria, South Africa, 50% of women in Mali, and eight out of 
every ten women in the Ivory coast participating in this practice.3,4 In a study done by Schroff et 
al., it was suggested that Indian women were generally two times more likely to use lightening 
products than Indian men. The statistics in Europe and Asia suggest 27-77% usage in different 
communities. The toxicity of the ingredients, such as mercury and hydroquinone, has been 
sufficient to ban the products from circulation in an open market in countries like Ghana, 
Zimbabwe, South Africa and Nigeria.5 The constitutive skin types that lighten their complexion 
tend to fall under the Fitzpatrick skin types IV-VII; individuals with skin types that are I-III 
would normally lighten their skin in cases of hyperpigmentation, melasma, or acne scars that 
may alter the color of the areas affected.6 The percentage of women who bleach their skin in the 
world correlates with the skin type distribution as illustrated by Table 1, which is based on 
modified figures from studies performed by Holcomb et al. and Bino et al.10, 11 Manufacturers 
and skin lightening product distributors do not warn users of the dangers of lightening skin 
INTRAVENOUS GLUTATHIONE AND DISEASE STATES 5 
   
 
because of how lucrative the industry is.15 The product market is estimated to reach $8 billion by 
2026 globally.7  
Table 1 
Fitzpatrick scale of skin types and their associated characteristics as they relate to the 
distribution of women who would practice skin lightening. 
 
Fitzpatrick Scale  
Photo type Sunburn and tanning 
criteria 
Constitutive skin color 
 
Heritage of photo type 
prevalence (but not 
limited to) 
I Always burn, never tan Very light Northern Europe, 
United Kingdom 
II Always burn, 
sometimes tan 
Light Europe, Scandinavia 
III Sometimes burn, 
always tan 
Intermediate Southern Europe, 
Central Europe 
IV Never burn, always tan Tan Mediterranean, Asia, 
Latino 
V Moderately pigmented Brown East India, Africa, 
Native Americans 
VI Heavily pigmented Dark brown to black Aboriginal, Africa 
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The agents for skin lightening are classified into different categories based on their mode 
of action on the skin. Hydroquinone and its derivatives arbutin and kojic acid, azelaic acid, 
mercury, and botanicals are classified as chemical tyrosine kinase inhibitors; niacinamide is a 
melanocyte transfer inhibitor; alpha and beta hydroxy acid are vitamin A derivatives and are 
classified as accelerators of epidermal turnover; vitamin C, vitamin E, ubiquinone, glutathione 
and coenzyme Q-10 are antioxidants; and topical corticosteroids are anti-inflammatory in 
nature.8 These have been used as agents to halt the production of eumelanin, which causes the 
brown pigment in skin. Many African countries have banned the distribution and sales of skin 
bleaching creams containing these agents due to harmful side effects such as hypopigmentation, 
skin sensitization and melanoma.9 
The effects of oral and topical applications of glutathione have been studied in higher 
proportions compared to intravenous glutathione. These studies have helped in establishing 
safety data. The Food and Drug Administration (FDA) of the Philippines declared dietary oral 
glutathione supplements as safe for use but have not approved the oral supplements in the case of 
skin lightening. Although the oral glutathione has not been declared safe to use, it is still 
manufactured and distributed. Due to the desire for an efficient treatment that is not localized to 
one part of the body the demand for intravenous glutathione has increased. However, due to 
limited information about the safety of intravenous applications of glutathione, organizations 
such as the Philippine Dermatological Society have issued a warning that the use of intravenous 
glutathione at high doses may be harmful to the recipient.12  
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Glutathione 
Glutathione (GSH) is a ubiquitous, low molecular weight thiol, and tripeptide consisting 
of γ-L-glutamyl-L-cysteinyl-glycine. GSH has one of the greatest antioxidant properties and is 
important to normal cell function because it maintains cellular redox balance. Glutathione is 
abundant in cells but it is remarkably reduced in pathological conditions such as HIV/AIDS, 
Parkinson’s disease, malnutrition, cancer, strokes, myocardial infarctions and others.49 
Glutathione is found in two forms, reduced (GSH) and oxidized (GSSG), as illustrated by Figure 
1.13 Glutathione is synthesized de novo from glutamate, cysteine and glycine through ATP 
hydrolysis. One oxidized glutathione molecule (GSSG) is made from two reduced glutathione 
molecules (GSH), which explains the higher ratio of GSH to GSSG intracellularly. Oxidative 
stress is indicated by a reduction in the ratio, as GSH has been used up to convert reactive 
oxygen species (ROS) like hydrogen peroxide (H2O2) to water, and by the decrease of NADPH, 
which reduces GSSG.  
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Figure 1. The glutathione redox cycle illustrating the function of the two glutathione 
variants. Figure 1 is adapted from a study performed by Sonthalia et al., and Ilkhani et al.15, 16 
The ratio of these two forms of glutathione can indicate oxidative health. A normal ratio 
of GSH/GSSG is greater than 100, while oxidative stress is indicated by a ratio of 10 or less.13 
De novo glutathione synthesis is catalyzed by glutamate cysteine ligase and glutathione 
synthetase enzymes through a two-step process that requires ATP. GSH is found in large 
concentrations of 5 mM intracellularly.13, 14 The most important functions of glutathione known 
to date are i) detoxification of xenobiotics, ii) catalysis of exchange reactions, iii) scavenging of 
free radicals and reactive oxygen species (ROS), iv) transport of amino acids across cell 
2 
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membranes, v) acting as a coenzyme in some processes of cellular metabolism and vi) 
maintenance of thiol groups of proteins and other molecules.15, 17 
Glutathione’s popularity in skin lightening treatments comes as a result of its anti-
melanogenic properties when it works as a tyrosinase inhibitor during melanogenesis (see Figure 
2).18 ROS directly activate tyrosinase. However, when GSH binds to the ROS, they are oxidized 
into a non-reactive form, inhibiting tyrosinase. GSH directly inhibits tyrosinase when its thiol 
groups react with the copper active site. Tyrosinase is mostly involved in the catalysis of 
dihydroxyindole (DHI) and dihydroxyindole carboxylic acid (DHICA) into DHI melanins and 
DHICA melanins, respectively. The presence of thiols such as GSH at the dopachrome stage of 
the pathway results in binding with dopaquinone to make thiolodopas. This pathway is favored 
due to the inhibition of the tyrosinases, causing the increased production of pheomelanins. Thiol 
groups found in GSH can directly inhibit tyrosinase by binding to its copper-containing active 
site.  The production of the brown pigment eumelanin is halted, resulting in the switch to 
production of pheomelanin, which is a red/orange pigment.20 This is one of three postulated 
mechanisms of action for GSH.  
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Figure 2. The Raper-Mason pathway shows the effect of the presence of GSH on the 
production of pheomelanin in melanogenesis. Figure 2 was adapted from studies by Sonthalia et 
al. and Davids et al.15, 20 
Depleted levels of GSH in cells have been found in Parkinson's disease, cadmium 
exposure, HIV/AIDS, macular degeneration, and other neurodegenerative disorders.13 
Supplemental dietary GSH has been tested as a treatment for liver abnormalities, deficient 
immunity, pre-term infant autism, chronic otitis media, Parkinson’s disease and other disorders. 
These supplements have been applied both orally and intravenously.19 GSH is a thiol-containing 
compound. Its mechanism of action was inferred from past studies that linked thiol-containing 
compounds (kojic acid, arbutin, hydroquinone) to skin lightening. The skin lightening effect of 
these compounds was discovered during their use in a study for Parkinson’s disease treatments.20 
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Compounds that act as scavengers for ROS, such as GSH, can slow down the effects of 
melanogenesis. Furthermore, if the compound has redox properties like glutathione, it can 
decrease melanin production by interacting with o-quinones or the thiol group at the active site 
of the enzyme tyrosinase.21 The active site of tyrosinase contains Cu2+ and soft Lewis bases as 
thiol groups are inclined to chelate soft Lewis acids such as Cu2+.48, 52 Furthermore, when 
cysteine residues are present in active site pockets of tyrosinase, they cause disulfide 
interchanges with the thiol groups. A larger network of inhibition is created when cysteine 
residues increase around the tyrosine active site.48 
Oral Glutathione 
Topical creams are slowly fading away in usage as their effects are restricted to the area 
of application, making oral lightening treatments the alternative. Oral glutathione treatments 
have increased in popularity due to the impression that they give the whole body a lighter 
appearance. However, this is contrary to scientific research.14 Torula yeast (Candida utilis) has 
been the main source of oral glutathione, which has been used as a dietary supplement. This 
derived glutathione has been the primary ingredient in supplements. Secondary ingredients 
include antioxidants like vitamin C.15 
Dosing of oral glutathione has been inconsistent between manufacturers as a result of 
insufficient studies, making it difficult to assess the side effects of this treatment. Oral 
glutathione has been made available in the form of pills and solutions.15 One manufacturer, 
Flawless Beauty and Skin, recommends a dosage of three pills that contain 900 mg of L-
glutathione.22 Minor ingredients include N-acetyl-L-cysteine (300 mg), alpha lipoic acid (225 
mg), L-methionine (150 mg), vitamin E (150 IU), vitamin B2, (7.5 mg), and selenomethionine 
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(300 mcg). According to the manufacturer, these ingredients were combined to enhance 
glutathione serum levels in the body.  This product emphasizes that it is not approved by the 
FDA even though it is manufactured in the United States of America.22 
In comparison, an Indian manufacturer recommends a dosage of 10-20 mg per kg body 
weight for use as an antioxidant or anti-aging medication. In contrast, in the case of skin 
lightening, the recommended dosage is 20-40 mg per kg body weight. Furthermore, the duration 
of treatment is dependent on the client’s skin color, with darker shades of skin requiring 
treatment for over two years, and lighter shades of skin needing one to three months of treatment 
until the desired outcome has been achieved. This product is recommended in combination with 
vitamin C (2000 mg per day) for the glutathione to be absorbed most efficiently. Each 
glutathione pill taken contains 1000 mg, and a client is prescribed one pill twice a day.24 These 
two products are small examples of how diverse the industry is in dosage and duration 
recommendations. Indeed, there is no scientific basis for the recommended dosage. 
Studies done by Kovacs-Nolan et al. on the fate of oral GSH have shown that it can cross 
the intestinal epithelium, but it is readily oxidized to GSSG.25 GSH is quickly digested by 
gamma-glutamyl transferase (GGT) in the upper jejunum into its constituent amino acids: 
cysteine, glycine and glutamate.26 It has been found that intracellular GSH is more effective 
when its constituent amino acids are taken on their own instead of GSH itself, as there is a higher 
concentration of GGT in the liver which further degrades the oral GSH that has been absorbed 
into the bloodstream after digestion. Oral cysteine is degraded in the digestive tract, but 
supplementing it in the form of N-acetylcysteine (NAC) increases the levels of cysteine because 
it is protected from degradation.13 Oral glutathione has a low bioavailability, and this may be the 
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motive behind the pursuit of intravenous (IV) glutathione.27 The estimated half-life of oral 
glutathione in plasma is 1.6 min.39 Additionally, it should be noted that any skin lightening 
treatments sought from this method are temporary as pheomelanin production is low and 
inconsistent.28 
Intravenous (IV) Glutathione 
IV glutathione has been recently introduced in the cosmetic industry to speed up the skin 
lightening process, and to have long-lasting effects. This method is controversial due to the lack 
of safety data regarding its use. Few research studies have been performed to date concerning IV 
glutathione despite many women, especially in the Philippines, using this as their primary skin 
lightening agent.15 The Philippine FDA released a statement warning of the toxic consequences 
to the nervous system, liver and kidneys and the development of the rare Stevens-Johnson 
syndrome with the continued used of IV glutathione. The greatest concern from the FDA is the 
incorrect administration of this treatment by untrained and non-medical personnel. In the black-
market areas that provide this service safety precautions may not be observed. The use of 
injections and a drip in non-sterile conditions can lead to the transmission of HIV as needles are 
shared, and the spread of different types of hepatitis. Overall, clients can experience embolisms 
caused by the introduction of intravenous air bubbles, and sepsis caused by pathogens and 
counterfeit glutathione.29 On a cellular level, increased serum levels of intravenous glutathione 
can lead to reductive stress that is just as toxic to the body as oxidative stress.32 
Research Question  
Despite insufficient data to support the use of glutathione as a skin lightening treatment, 
it is still used. This study will investigate the ability of glutathione to lighten skin. First, the 
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mechanism of action that glutathione takes to lighten skin will be investigated to bridge the gap 
that exists between topical, oral and IV administration.  Then, the effects of oral and topical 
glutathione in the body will be investigated by studying their biochemical mechanisms to 
compare them to IV glutathione. This study will also explore the side effects of glutathione when 
used for its melanogenic properties. Finally, by looking into the pathogenesis of disease, possible 
effects of IV administration of glutathione will be mapped to determine the potential long-term 
consequences of skin lightening. 
Literature Summary of Glutathione Skin Lightening Products 
IV glutathione has not been officially recognized as a skin lightening agent. Its mode of 
action has not been observed. Furthermore, only a few studies have been conducted to date to 
observe the efficacy of oral and topical glutathione in skin lightening. The following studies 
were published over four years ago, and there is a need for more recent data as glutathione is 
increasing in popularity. Table 2a and 2b are a compilation of known studies that may aid in a 
proposal of a mechanism of action. These tables are adapted from Table 1 published from the 
study by Sonthalia et al.15  
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Table 2a 
Investigations of glutathione as a skin lightening treatment topically and orally. 
Type of 
Glutathione 
Application 
Topical Oral (capsules) 
Study 
Reference  
Watanabe et al. 22 Weschawalit & Asawanoda 
44 
Arjinpathana and 
Asawononda 46 
Year 2014 2016 2010 
Subject 
Information 
30 healthy Filipino 
females; tan;  
Fitzpatrick skin types III 
or IV; 
30-50 years of age 
60 healthy females 
randomized into 3 groups; 
20-50 years of age 
60 healthy medical 
school students; 18 
males and 42 females;  
19-22 years of age 
Study 
Design 
Randomized, double-
blind, placebo-
controlled, matched-pair 
study 
Randomized, placebo 
controlled, three-arm study 
Randomized, double-
blind, placebo-
controlled, two-arm 
study 
Methods 
Applied 
0.5 g of lotion comprised 
of 2% (w/w) GSSG or 
placebo without GSSG 
randomly assigned and 
spread evenly to either 
250 mg/day of GSH,  
250 mg/day of GSSG or 
placebo (dibasic calcium 
phosphate), randomly 
assigned to subjects  
250 mg glutathione or 
placebo capsules 
taken twice daily on 
an empty stomach for 
4 weeks, block-
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left or right cheek of 
each subject 
randomized 
assignment to subjects 
Parameters 
Evaluated 
Measured every 2 weeks 
for 10 weeks: 
1) Skin whitening using 
Mexameter for melanin 
index (mexameter is a 
tool used to measure 
melanin and hemoglobin 
levels through 
absorption/reflection of 
light) 
2) Skin moisture 
3) Skin firmness using a 
Triplesense TR-3 sensor 
device 
4) Efficacy against 
wrinkle reduction by 
observing “crow’s feet” 
5) Skin smoothening  
 
Measured every 4 weeks: 
 
1) Melanin index 
2) Presence of UV spots 
3) Transepidermal water 
loss 
4) Water contents 
5) Elasticity  
 
Measured at baseline 
and after 4 weeks: 
1) Melanin index 
using a Mexameter: 
Sun exposed areas: 
i) Face (both sides), 
2.5 cm caudally from 
the lateral canthi 
ii) Extensor surfaces 
of both forearms, 7 
cm above the ulnar 
styloid processes  
Sun protected areas: 
i) Upper, inner arms, 
10 cm from axillary 
vault 
ii) Standardized 
photographs were 
taken using a VISIA 
CR system to 
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quantitatively 
measure: 
a) UV spots 
b) Pores  
c) Skin evenness  
Subject Self-
Evaluation 
Scoring pattern used to 
determine skin whitening 
and smoothening: 
-3 = marked 
deterioration 
-2 = moderate, visibly 
uneven deterioration 
-1 = slight deterioration 
0 = no apparent change/ 
improvement 
1 = slight 
change/improvement 
2 = visible 
change/improvement 
(<50% lightening of skin 
color) 
No subject participation in 
evaluation  
Used global 
assessment by scoring 
with a 4-point scale: 
4 = very satisfactory 
3 = moderately 
satisfactory 
2 = minimally 
satisfactory 
1 = not satisfactory 
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3 = marked 
improvement/ significant 
change (uniform skin 
whitening, >80% of 
application area)  
Safety and 
Side Effects 
Listed 
Well-tolerated; all 
subjects completed 
study; 1 subject had mild 
erythema on days 2 and 
3; no reports of 
unwanted symptoms  
Well-tolerated 
 
Well-tolerated; 1 
subject in glutathione 
group experienced 
flatulence; 1 subject 
in placebo group 
experienced 
constipation  
Follow-up None after 10 weeks of 
study 
None after study duration  None after study 
duration 
 
 
 
 
 
Study 
Results 
1) Skin lightening 
melanin index: 
A) Placebo - decreased 
slightly after 10 weeks 
(Week 0: 274.13 [+/-] 
25.81 vs. Week 10: 
265.50 [+/-] 25.82) 
1) Both GSH and GSSG 
caused decreased melanin 
indices  
2) GSH more effective in 
wrinkle improvement 
3) GSH and GSSG 
increased skin elasticity in 
1) GSH group had 
greater decrease in 
melanin index than 
placebo group on sun-
exposed areas  
2) Smaller number of 
UV spots developed 
in subjects on 
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B) GSSG lotion –
decreased after 10 weeks 
(Week 0: 272.77 [+ or -] 
26.17 vs. Week 10: 
243.47 [+ or -] 26.31) 
2) Moisture index values 
were higher at GSSG 
sites than placebo sites 
3) Curvature and keratin 
values were significantly 
lower in GSSG sites than 
placebo sites  
4) Elasticity values did 
not show a remarkable 
difference between 
placebo and GSSG lotion  
both sun exposed and sun- 
protected skin   
 
glutathione treatment; 
an increase in skin 
evenness and a 
reduction in pore size 
were reported with 
the treatment 
3) Subjects reported 
an average score of 
3.06 for satisfaction 
Limitations  Small study size, short 
duration and no follow-
up; limited to women of 
Fitzpatrick skin type III-
VI; results may be 
Study had insufficient data 
to analyze limitations 
Plasma glutathione 
levels not measured; 
study duration was 
short and no follow 
up  
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limited to Filipino 
women  
Proposed 
Mechanism 
of Action  
A) Conversion of GSSG 
to GSH in epidermis  
B) GSH activates 
pheomelanin pathway 
Unavailable GSH activates 
pheomelanin pathway 
 
Table 2b 
Investigations of glutathione as a skin lightening treatment orally and intravenously. 
Type of 
Glutathione 
Application 
Oral (buccal lozenges)  Intravenous 
Study 
Reference  
Handog et al. 45  Zubair et al. 32 
Year 2015 2016 
Subject 
Information 
30 Filipino females who work as 
medical personnel, Fitzpatrick 
skin types IV – V, with melanin 
indices of ≥ 20 out of 99;  
22-42 years of age 
50 female test subjects enrolled, 32 had 
data recorded from them and were 
divided into 2 groups: Group A skin 
types match group B skin types; 
25-47 years of age  
Study Design Open label, singe–arm pilot study Placebo-controlled 
Methods 
Applied 
Identical bottles containing 30 
lozenges (500 mg of GSH) were 
given to each subject 
Group A: 16 subjects given IV 
glutathione and vitamin C (injection of 
GSH Detox Forte ®, 1200 mg) 
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Subjects kept one lozenge in their 
mouth, against their inner cheek 
(buccal mucosa) 
every morning, until completely 
dissolved 
Control Group B: 16 subjects given IV 
saline as placebo (injection of 5 mL 
saline, 10 mL distilled water) 
 
2 unexposed body sites were chosen 
(upper inner arm below axilla and upper 
outer thigh of all patients). 
Parameters 
Evaluated 
Evaluation done every 2 weeks 
for 8 weeks: 
1) Portable Mexameter used to 
measure melanin index 
2) Melanin indices taken from 
sun-exposed area (extensor 
surface of wrist) and sun-
protected area (mid sternum) 
3) Liver function tests, serum 
glutamic pyruvic transaminase 
(SGPT), complete blood count 
(CBC) and serum glutamic 
oxaloacetic transaminase (SGOT) 
were done at baseline  
 
Administration for 6 weeks and 2 
independent observers evaluated: 
 
Skin tone measured with Taylor 
hyperpigmentation scale (tool consisting 
of 15 uniquely colored plastic cards with 
hues that apply to Fitzpatrick skin types 
I-IV and is used to visually assess 
complexion), cards are used to analyze 
change from darker shades to light 
shades 47 
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Subject Self-
Evaluation 
Used global assessment scores to 
determine skin lightening: 
None = 0  
Mild change = 1  
Moderate = 2   
Obvious = 3 
Very marked = 4 
No subject participation in evaluation  
Safety and 
Side Effects 
Listed 
Well-tolerated; 29 out of 30 
subjects completed the study; 30th 
subject complained of soreness in 
gums due to lozenge 
administration; another subject 
complained of chalky taste but 
completed study.  
 
CBC, SGPT and SGOT values 
remained normal at week 8.  
 
 
Not well-tolerated; 32 out of 50 
completed study; 8 subjects from group 
A had deranged liver function tests 
(defined as 1.5 times above reference 
range), and 1 subject developed 
anaphylactic shock; all were excluded 
from results. 
9 control from group B who matched the 
skin types of subjects excluded from 
group A were also excluded to keep 
study standardizations  
 
Side effects in 25 subjects in group A: 
Feeling warmth during injection (44%)  
Abdominal cramps (40%) 
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Abnormal liver functions (32%) 
Feeling of heart sinking (28%) 
Diarrhea (16%) 
Paresthesia (16%) 
Dizziness (12%) 
Anaphylactic shock (4%) 
Vomiting (4%) 
Follow-Up None after the duration of study 2, 4, 6 months after end of 
administration  
Study Results 1) In sun-exposed area:  
At week 8, 100% of subjects 
experienced a reduction in their 
melanin indices (p<0.0001) from 
week 0; significant skin 
lightening effects only showed 
after week 2 
2) In sun-protected area: 
At week 8, 100% of subjects 
experienced a reduction in their 
melanin indices from week 0 
3) 27/30 subjects (90%) evaluated 
their skin as having undergone 
1) GSH group A skin improvement, 
n=16 
0 months (after 12 injections): 6 (37.5%) 
2 months: 3 (18.7%) 
4 months: 3 (18.7%) 
6 months: 1 (6.2%) 
2) Placebo group B skin improvement, 
n=16 
0 months (after 12 injections): 3 (18.7%) 
2 months: 2 (12.5%) 
4 months: 0 (0%) 
6 months: 0 (0%) 
Not very effective for skin lightening  
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moderate lightening (score 2 out 
of 4); 3/30 subjects (10%) 
evaluated their skin having 
undergone mild skin lightening 
(score 1 out 4)  
Limitations  Small study population and 
duration  
No control used and no follow-up 
Blood GSH levels were not 
measured  
Blood GSH levels were not measured 
Taylor hyperpigmentation tool is more 
useful when used subjectively but a 
Mexameter is more useful to measure 
melanin index objectively and accurately 
50 
Small study population and short 
duration  
Mechanism of 
Action  
GSH used mucosal route to get to 
epidermis all around the body 
GSH absorption increased when 
administered with vitamin C 
 
Analysis of the Literature  
Most of the above studies were conducted in Southeastern Asia countries, where 
residents usually have the Fitzpatrick skin types III-IV and olive/tan skin (Table 1). The results 
displayed that glutathione in general does help with skin lightening, but the most effective 
treatment was through oral glutathione administration. Oral administration also appeared to be 
the safest because it had minor or no side effects on the subjects compared to IV glutathione. 
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GSH and GSSG both had the same effect in reducing the melanin index of the skin. This would 
be expected because GSSG can be easily reduced into GSH by glutathione reductase (see Figure 
1) to be used as GSH in the Raper-Mason pathway. These studies suggested that glutathione has 
skin lightening properties when applied topically and orally, and the proposed mechanism was 
through the shifting of the Raper-Mason pathway to produce pheomelanin instead of eumelanin. 
According to the study done by Zubair et al., IV glutathione does not appear to retain its skin 
lightening properties over time.32 The missing link in the studies was the lack of data pertaining 
to serum glutathione levels. By monitoring the levels of GSH in the blood, the metabolism of IV 
glutathione may be investigated, and mechanisms of action proposed.  
Proposed Disease States Directly and Indirectly Correlated to IV Glutathione  
The study done by Zubair et al. in 2016 to test the efficacy of IV glutathione against a 
placebo in skin-lightening is one of the only studies published to date. The data from this 
experiment is helpful because it gives the potential effects of using IV glutathione over long 
periods of time. Of all the side effects, notably 40% of volunteers from group A experienced 
abdominal cramps, 32% reported deranged liver functions and 16% reported diarrhea and 
paresthesia. The control group B did not record any adverse side effects, which suggests that 
intravenous glutathione was the cause for the side effects. The main objective of the experiment 
was to observe changes in skin color: 37.5% of women were observed to have a change in skin 
color immediately after the completion of 12 injections. By the last observation at six months, 
only 1 out of the 16 women who completed the treatment showed a consistency in skin color 
improvement.32 Nine women had to stop treatment due to adverse side effects. Eight out of the 
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nine women experienced issues with their livers, and one suffered from anaphylaxis due to the 
treatment (Table 2b).  
Reductive Stress Can Cause Oxidative Stress  
Reductive stress is the opposite of oxidative stress and happens as a result of the redox 
imbalance of the species GSH/GSSG, nicotinamide adenine dinucleotide (NAD+)/NADH and 
phosphorylated NAD+ (NADP+)/NADPH; these species are important in the maintenance of a 
homeostatic environment for cells. An increase in the formation of GSSG is a marker of 
oxidative stress.33 Increased levels of intracellular GSH can induce pro-oxidant activity and halt 
its antioxidant properties towards ROS.34, 35 Reductive stress is known to mostly contribute to 
inflammatory disease in contexts such as cancer, pulmonary hypertension and hypertrophic 
cardiomyopathy.33 ROS are beneficial in the body for redox homeostasis, and well-functioning 
cardiovascular and immune systems. For example, in redox regulation, the ROS react with the 
amino acid cysteine on proteins, which is important in signaling pathways. ROS are also 
important in the cell cycle and in influencing apoptosis. ROS can bind to the mitogen-activated 
kinase, which triggers the apoptotic cascade.51 Consistent reductive stress caused by a shortage 
of ROS can cause oxidative stress as a result of negative feedback: redox proteins can donate 
excess electrons to O2 which generates ROS such as superoxide (O2
- ). An increased 
concentration of ROS leads to oxidative stress, which triggers increased action by the ROS 
scavengers, and may trigger a reductive stress crisis again.36 This cycle can cause cellular 
damage as homeostasis is disrupted.  
Increased production of pheomelanin. GSH is imperative for the melanogenesis 
pathway to produce pheomelanin, and its continued production is sustained by high levels of 
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cysteine that interact with the DOPA-quinone as illustrated in Figure 2.43 The use of IV 
glutathione, as demonstrated by the study conducted by Zubair et al., can alter skin color. 
However, the changes were temporary.32 People with lighter skin types (Fitzpatrick skin types I-
III) are 70 times more at risk to develop skin cancer compared to those who fall under the 
Fitzpatrick skin types IV-VI.37 Eumelanin is regarded as the more protective of the two types of 
melanin as it is not implicated in melanogenesis as much as pheomelanin.37 While the exact 
mechanism is unknown, pheomelanin production increases ROS in melanocytes, and therefore 
decreases glutathione stores within the cell. The introduction of high levels of intravenous GSH 
can help to recover depleted levels of the antioxidant in the cell and maintain the level of 
cysteine for pheomelanin production, rather than exacerbate oxidative stress in melanocytes.38   
A study performed by Nasti and Timares about the roles of eumelanin and pheomelanin 
in the susceptibility to skin cancer concluded that there was a correlation between different 
strains of mice (agouti and yellow coats) with high pheomelanin production and a higher risk of 
developing melanoma.37 More research needs to be done to determine the direct link between 
pheomelanin and melanoma, and how other factors such as UV radiation contribute to it.  
It has been found that GSH is vital for metastatic melanoma growth. In a study done by 
Carretero et al. to investigate the link between glutathione content and the activity of metastatic 
liver cancer cells using B16 melanoma cells, it was observed that GSH regulated energy 
metabolism and increased cell growth.42 GSH is produced in vivo, but low levels of cysteine 
cause a lag in GSH synthesis. When cysteine was supplemented in this study, growth of the B16 
melanoma cells was expedited, as cysteine is the rate-limiting step in GSH production.42 
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Exogenous intravenous supplementation of glutathione could possibly increase cancer growth as 
it may supply the much-needed cysteine when GSH is broken down intracellularly.  
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). These are 
rare, life-threatening conditions that are caused by an adverse immune reaction to medications. 
Medications for these conditions include anticonvulsants, allopurinol, sulfonamides, antibiotics 
and non-steroidal anti-inflammatory drugs. SJS and TEN physically manifest themselves in the 
form of mucocutaneous blisters that may result in epidermal detachment and tissue necrosis.30 
Skin lesions appear, followed by symptoms that resemble a respiratory infection such as fever, 
headache and sore throat. People who suffer from HIV/AIDS, lupus, or compromised immune 
systems are usually more susceptible to suffering from SJS and TEN.31 The Philippine FDA 
mentioned that the use of intravenous glutathione can cause SJS/TENS. The mechanism of how 
this could occur is still under investigation, and little is known about the role of glutathione in 
this disease state.  
Theoretically, glutathione may increase the risk of SJS/TEN occurring through cellular 
redox imbalance. High levels of ROS that could be caused by the reductive stress/oxidative 
stress cycle trigger apoptosis to occur.  There are different mechanisms of the pathogenesis of 
these diseases, but one that may involve glutathione is keratinocyte apoptosis, followed by 
necrosis.40 Apoptosis of the cell occurs as a result of damage to the mitochondria. The ROS may 
activate nuclear transcription factors such as tumor necrosis factor alpha (TNF-α) to begin the 
early stages of apoptosis, or indirectly cause apoptosis through cell damage by disrupting plasma 
membrane lipids and mobilizing Ca2+, which leads to early apoptosis. Increased levels of GSH 
disrupt the ionic gradient of the mitochondria, causing it to rupture, leading to late necrosis.41 
INTRAVENOUS GLUTATHIONE AND DISEASE STATES 29 
   
 
This is only a suggested mechanism to explain how increased glutathione serum levels may be 
related to SJS/TEN. More experimental data needs to be compiled as there is no definitive link to 
SJS/TEN, except the report from the Philippine FDA. The novelty of IV glutathione being used 
as a skin lightening agent is an opportunity for more experimentation to take place to investigate 
its effects.  
Conclusion 
This literature review has established that women, more than men, undergo skin 
lightening treatments. This is evidenced by most of the studies being conducted on women, and 
women having a stronger desire to achieve a sense of beauty by having a lighter complexion.5 
The pursuit of lighter skin is not only fueled by current beauty standards, but also social 
acceptance and higher social status. The Fitzpatrick scale in Table 1 showed that the photo types 
IV-VI are more likely to undergo skin lightening treatments, which correlates with the certain 
regions in the world such as Asia, East India, Southeastern Asia and Africa.  
Although supplemental oral glutathione has been declared as safe, oral glutathione for 
skin lightening reasons has not been approved by the Philippine FDA. Use of the intravenous 
version of this skin lightening treatment has been warned against by the Philippine FDA due to 
the adverse side effects reported. Despite this, intravenous glutathione is still sold on the market, 
and still being used. Using glutathione could be risky if it is administered by untrained personnel. 
Dangerous side effects may result, including the transmission of HIV and different forms of 
hepatitis from recycled needles. Furthermore, there is an inconsistency with the dosing of 
glutathione for skin lightening among manufacturers, which may pose a danger to users as 
excessive glutathione may lead to liver toxicity. Studies exploring the anti-melanogenic effects 
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of glutathione are few, and those reporting data are limited to Southeastern Asian women. 
Women who use skin lightening treatments may use glutathione (topical, oral or IV) over long 
periods of time, and unfortunately studies to date were too short to determine long-term 
consequences.  
The mechanism of action of glutathione established from research is the inhibition of the 
tyrosinase enzyme. The inhibition of the tyrosinase active site shifts eumelanin production to 
pheomelanin. The injection of IV glutathione has been shown to raise serum GSH, which could 
lead to reductive stress as there is a large concentration of GSH in cells. By negative feedback, 
this could result in oxidative stress. Theoretically, increased ROS may be the reason behind the 
aggravation of conditions such as SJS/TEN. Increased pheomelanin production may cause the 
user to be at higher risk of suffering from melanoma. This study was inconclusive in establishing 
a direct link between IV glutathione and SJS/TEN.  
GSH is manufactured de novo because it is important for bodily functions. Normal 
cellular actions require GSH to prevent tissues from undergoing oxidative stress as it is the 
greatest antioxidant. Since it is already found in high concentrations in the body, its 
supplementation at high doses could be toxic for the body, especially if taken in unregulated 
doses. The use of glutathione is not based on scientific findings and could eventually cause more 
harm than good. Oral glutathione may have been established as a lightening product, but 
intravenous glutathione is not effective in skin lightening and may lead to redox crises in the 
body with continued use.  
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Future Experimentation 
The literature in Table 2 showed that none of the experiments monitored GSH serum 
levels which could play an important role in outlining the mechanism of glutathione metabolism. 
Since glutathione is made up of cysteine, glutamate and glycine, one of these amino acids could 
be tagged. The half-life of glutathione is short because it is digested to its constituent amino 
acids. Cysteine could be tagged as it is imperative in the production of pheomelanin. The urine of 
subjects could then be monitored for tagged cysteine molecules to observe if GSH was excreted 
due to excess levels in the blood. More experiments need to be done on topical, oral and 
intravenous methods to establish safe doses and to monitor the effects of taking glutathione for 
long durations. Finally, the Philippine FDA suggested the occurrence of SJS/TEN with the use of 
IV glutathione. Although rare, it is theoretically feasible, and a study could be conducted to 
determine if glutathione directly causes this condition, and if reductive stress plays a role.  
 
 
 
 
 
 
 
 
 
 
INTRAVENOUS GLUTATHIONE AND DISEASE STATES 32 
   
 
References  
1. Charles C. Skin bleaching, self-hate, and black identity in Jamaica. J Black Stud 2003; 
33:711-28.  
2. Jacobs M, Levine S, Abney K, Davids L. Fifty shades of African lightness: A bio-
psychosocial review of the global phenomenon of skin lightening practices. J Public 
Health Afr 2016; 7:552.  
3. Gbenga, A. (2004).  Nigeria: Bleaching body practices [WWW document]. URL 
http://www.youthxchange.net/main/nigeriableachingbodypractices.asp. [accessed on 10 
January 2020]. 
4. Blay, A. Skin bleaching and global white supremacy: By way of introduction. J Pan Afr 
Stud 2011; 4:4–46. 
5. Shroff H, Diedrichs PC, Craddock N. Skin Color, Cultural Capital, and Beauty Products: 
An Investigation of the Use of Skin Fairness Products in Mumbai, India. Front Public 
Health 2018; 5:365-70.  
6. Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol 
Ther 2007; 20: 308-313.  
7. Statistics Market Research Consulting Pvt. Ltd. (2019). Global skin lightening products 
market is expected to reach $8011.17 million by 2026 [WWW document] 
https://www.prnewswire.com/news-releases/global-skin-lightening-products-market-is-
expected-to-reach-8011-17-million-by-2026--300906859.html [accessed 21 January 
2020]. 
INTRAVENOUS GLUTATHIONE AND DISEASE STATES 33 
   
 
8. Couteau C, Coiffard L. Overview of skin whitening agents: Drugs and cosmetic 
products. Cosmetics 2016; 3:1-16. 
9. Sarkar R, Arora P, Garg KV. Cosmeceuticals for hyperpigmentation: What is available? J 
Cutan Aesthet Surg 2013; 6:4-11.  
10. Bino SD, Duval C, Bernard F. Clinical and biological characterization of skin 
pigmentation diversity and its consequences on UV impact. Int J Mol Sci 2018; 19, 2668-
80.  
11. Holcomb NC, Bautista R, Jarrett SG, et al. Chapter eight, cAMP-mediated regulation of 
melanocyte genomic instability: A melanoma-preventive strategy. Advances in Protein 
Chemistry and Structural Biology, Academic Press. 2019: 247-95. 
12. Dofitas BL, Asuncion EB, Nisce-Anisco KC, et al. (2018). Public advisory on glutathione 
as a “skin whitening” agent from Philippine glutathione advisory committee 2018. 
https://pds.org.ph/public-advisory-on-glutathione-as-a-skin-whitening-agent/. [accessed on 
18 January 2020]. 
13. Pizzorno J. Glutathione! Integr Med (Encinitas, Calif.) 2014; 13:8–12. 
14. Sonthalia S, Sarkar R. Glutathione for skin lightning: an update. Pigment Int 2017; 4:3-6. 
15. Sonthalia S, Daulatabad D, Sarkar R. Glutathione as a skin whitening agent: Facts, myths, 
evidence and controversies. Indian J Dermatol Venereol Leprol 2016; 82:262-72. 
16. Ilkhani F, Hosseini B, Saedisomeolia A. Niacin and oxidative stress: A mini-review. J 
Nutri Med Diet Care Last 2016; 2:014. 
17. Meister A, Tate SS. Glutathione and related gamma-glutamyl compounds: Biosynthesis 
and utilization. Annu. Rev. Biochem, 1976; 45:559-604. 
INTRAVENOUS GLUTATHIONE AND DISEASE STATES 34 
   
 
18. Sonthalia, S, Jha AK, Lallas A et al. Glutathione for skin lightening: a regnant myth or 
evidence-based verity? Dermatol Pract Concept 2018; 8:15–21. 
19. Hauser RA, Lyons KE, McClain T, Carter S, et al. Randomized, double-blind, pilot 
evaluation of intravenous glutathione in Parkinson’s disease. Mov Disord 2009; 24:979–
83. 
20. Davids LM, van Wyk JC, Khumalo NP. Intravenous glutathione for skin lightening: 
Inadequate safety data. S Afric Med J 2016; 106: 782-86.  
21. Briganti S, Camera E, Picardo M. Chemical and instrumental approaches to treat 
Hyperpigmentation. Pigment Cell Res; 16: 101-110.  
22. Watanabe F, Hashizume E, Chan GP, Kamimura A. Skin-whitening and skin-condition-
improving effects of topical oxidized glutathione: a double-blind and placebo-controlled 
clinical trial in healthy women. Clin Cosmet Investig Dermatol 2014; 7: 267–274.  
23. Flawless Beauty and Skin. New Relumins Advance White Active Glutathione Complex – 
Oral Whitening Formula Capsules with 6x Boosters [WWW document]. 
https://www.flawlessbeautyandskin.com/NEW-Relumins-Advance-White-Active-
Glutathione-Complex-Oral-Whitening-Formula-Capsules-with-6X-Boosters-Whitens-
repairs-rejuvenates-skin_p_581.html [accessed 18 January 2020] 
24. Bangalore Classifieds. (2020). Glutathione Skin Lightening Pills in India [WWW 
document]. http://www.bangalore.click.in/glutathione-skin-lightening-pills-in-india-c75-
v4148389. [accessed 18 January 2020]. 
INTRAVENOUS GLUTATHIONE AND DISEASE STATES 35 
   
 
25. Kovacs-Nolan J, Rupa P, Matsui T, et al. In vitro and ex vivo uptake of glutathione (GSH) 
across the intestinal epithelium and fate of oral GSH after in vivo supplementation. J Agric 
Food Chem 2014; 62:9499–9506. 
26. Gould RL, Pazdro R. Impact of supplementary amino acids, micronutrients, and overall 
diet on glutathione homeostasis. Nutrients 2019; 11:1055-1056.  
27. Dilokthornsakul W, Dhippayom T, Dilokthornsakul P. The clinical effect of glutathione 
on skin color and other related skin conditions: A systematic review. J Cosmet Dermatol 
2019; 18: 728– 737.  
28. Hanigan MH. Gamma-glutamyl transpeptidase: redox regulation and drug resistance. Adv 
Cancer Res 2014; 122:103–141.  
29. Food and Drug Administration Philippines. (2019). [WWW document] 
https://ww2.fda.gov.ph/attachments/article/596859/FDA%20Advisory%20No.2019-
182.pdf [accessed 18 January 2020]. 
30. Zimmerman D, Dang NH. Stevens–Johnson Syndrome (SJS) and toxic epidermal 
necrolysis (TEN). In: Oncologic Critical Care (Nates J, Price K, eds). Springer, 
Cham., 2019. 
31. Ciccacci C, Latini A, Politi C. et al. Impact of glutathione transferases genes 
polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN 
susceptibility. Eur J Clin Pharmacol 2017: 73, 1253–1259. 
32. Zubair S, Hafeez S, Mujtaba G. Efficacy of intravenous glutathione vs. placebo for skin 
tone lightening. J of Pakistan Assoc Derma. 2016; 26:177-181.  
INTRAVENOUS GLUTATHIONE AND DISEASE STATES 36 
   
 
33. Pérez-Torres I, Guarner-Lans V, Rubio-Ruiz ME. Reductive stress in inflammation-
associated diseases and the pro-oxidant effect of antioxidant agents. Int J Mol Sci 2017; 
18:2098.  
34. Xiao W, Loscalzo J. Metabolic responses to reductive stress. Antioxidants & Redox 
Signaling. 2019; 0: 2020.  
35. Peris E, Micaef, Paul A, et al. Antioxidant treatment induces reductive stress associated 
with mitochondrial dysfunction in adipocytes. J Biol Chem 2018; 10: 1-23. 
36. Korge P, Calmettes G, Weiss JN. Increased reactive oxygen species production during 
reductive stress: The roles of mitochondrial glutathione and thioredoxin reductases. 
Biochem Biophys Acta 2015; 1847:514–525.  
37. Nasti TH, Timares L. MC1R, eumelanin and pheomelanin: their role in determining the 
susceptibility to skin cancer. Photochem and Photobio 2015; 91: 188–200. 
38. Morgan AM, Lo J, Fisher DE. How does pheomelanin synthesis contribute to 
melanomagenesis? Two distinct mechanisms could explain the carcinogenicity of 
pheomelanin synthesis. Bioessays 2013; 35:672–676.  
39. Bruggeman BK, Storo KE, Fair HM, Wommack AJ, Carriker CR, Smoliga JM. The 
absorptive effects of orobuccal non-liposomal nano-sized glutathione on blood glutathione 
parameters in healthy individuals: A pilot study. PLoS One 2019; 14: e0215815. 
40. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet 
J Rare Dis 2010; 5:39.  
41. Paquet P, Pierard GE. Toxic epidermal necrolysis: Revisiting the tentative link between 
early apoptosis and late necrosis (Review). Int. J. Mol. Med. 2007; 19:3-10. 
INTRAVENOUS GLUTATHIONE AND DISEASE STATES 37 
   
 
42. Carretero J, Obrador E, Anasagasti MJ et al. Growth-associated changes in glutathione 
content correlate with liver metastatic activity of B16 melanoma cells. Clin Exp 
Metastasis 1999; 17:567–574. 
43. Tanaka H, Yamashita Y, Umezawa K et al. The pro-oxidant activity of pheomelanin is 
significantly enhanced by UVA irradiation: benzothiazole moieties are more reactive than 
benzothiazine moieties. Int J Mol Sci 2018; 19:2889.  
44. Weshawalit S, Asawanonda P. Effects of oral glutathione on skin appearances: a 
randomized placebo-controlled study. J Am Acad Dermatol 2016; 74: AB16 
45. Handog EB, Datuin MSL, Singzon IA. An open‐label, single‐arm trial of the safety and 
efficacy of a novel preparation of glutathione as a skin‐lightening agent in Filipino 
women. Int J Dermatol 2016; 55: 153-157.  
46. Arjinpathana N, Asawanonda P. Glutathione as an oral lightening agent: A randomized, 
double-blind, placebo-controlled study. J Dermatol Treat 2012; 23:97-102. 
47. Taylor SC, Arsonnaud S, Czernielewski J. The Taylor Hyperpigmentation Scale: a new 
visual assessment tool for the evaluation of skin color and pigmentation. Cutis 2005; 
76:270-4. 
48. Yong-Doo P, Lyou Y, Hahn H et al. Complex inhibition of tyrosinase by thiol-composed 
Cu2+ chelators: A clue for designing whitening agents. J Biomol Struct Dyn 2006; 24: 131–
138.  
49. Wu G, Fang Y, Yang S et al. Glutathione metabolism and its implications for health. J 
Nutr 2004; 134:489–492. 
INTRAVENOUS GLUTATHIONE AND DISEASE STATES 38 
   
 
50. Treesirichod A, Chansakulporn S, Wattanapan P. Correlation between skin color 
evaluation by skin color scale chart and narrowband reflectance spectrophotometer. Indian 
J Dermatol 2014; 59:339–342. 
51. Patel R, Rinker L, Peng J et al. Reactive Oxygen Species: The Good and the Bad, Reactive 
Oxygen Species (ROS) in Living Cells (Cristiana Filip and Elena Albu, eds) IntechOpen, 
2017:8–16.     
52. Bjørklund G, Crisponi G, Nurchi VM et al. A review on coordination properties of thiol-
containing chelating agents towards mercury, cadmium, and lead. Molecules. 2019; 
24:3247.  
